ONCOLYTICS BIOTECH INC 8-K

What Happened

• On April 6, 2026, Oncolytics Biotech, Inc. announced via press release that it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss plans for a single‑arm pivotal study evaluating pelareorep in combination with a checkpoint inhibitor in squamous cell anal carcinoma (SCAC). The press release is included as Exhibit 99.1 to the Form 8‑K.

Key Details

• Filing date: April 6, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Topic: FDA Type C meeting to discuss design/plan for a single‑arm pivotal trial of pelareorep + a checkpoint inhibitor in SCAC.
• Exhibit: Press release attached as Exhibit 99.1.
• Report signed by Kirk Look, Chief Financial Officer, on April 6, 2026.

Why It Matters

• An FDA Type C meeting to discuss a pivotal study is a material regulatory milestone: it addresses trial design and pathway toward a potential approval-enabling study for pelareorep in a rare cancer indication (SCAC).
• For investors, progress in regulatory planning can affect development timelines, program value, and future clinical-readout expectations; however, this filing reports a meeting to discuss plans, not FDA approval or the start/completion of a pivotal trial.